Latest Ratios: P/E Ratio 11.0x · EV/EBITDA 5.7x · ROE 20.8%. (2018–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $1.9B | $2.2B | $2.0B | $2.0B | $3.4B | $2.5B | $2.1B | — | — |
| Enterprise Value | $1.4B | $1.7B | $1.7B | $1.8B | $3.3B | $2.5B | $2.1B | — | — |
| P/E Ratio → | 11.03 | 13.81 | 13.71 | 15.16 | 18.55 | 73.52 | — | — | — |
| P/S Ratio | 1.93 | 2.52 | 2.79 | 3.35 | 7.69 | 8.27 | 13.09 | — | — |
| P/B Ratio | 2.22 | 2.52 | 3.02 | 4.18 | 8.36 | 13.54 | 21.52 | — | — |
| P/FCF | 5.92 | 6.30 | 9.11 | 8.90 | 23.33 | 25.69 | — | — | — |
| P/OCF | 5.49 | 6.29 | 9.06 | 8.89 | 23.30 | 25.61 | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 1.93 | 2.41 | 3.15 | 7.57 | 8.14 | 12.88 | — | — |
| EV / EBITDA | 5.71 | 7.18 | 8.00 | 8.47 | 23.08 | 23.37 | 75.55 | — | — |
| EV / EBIT | 6.71 | 7.30 | 8.22 | 9.29 | 26.84 | 40.34 | — | — | — |
| EV / FCF | — | 4.82 | 7.86 | 8.36 | 22.97 | 25.30 | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 77.2% | 77.2% | 78.1% | 79.2% | 80.9% | 81.8% | 82.6% | 73.7% | — |
| Operating Margin | 24.0% | 24.0% | 26.7% | 33.0% | 27.4% | 28.7% | 10.6% | -2433.8% | — |
| Net Profit Margin | 18.3% | 18.3% | 20.4% | 22.1% | 41.4% | 11.3% | -23.1% | -2535.1% | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| ROE | 20.8% | 20.8% | 25.8% | 29.6% | 61.6% | 24.4% | -86.3% | -434.6% | -48.9% |
| ROA | 14.0% | 14.0% | 16.1% | 17.4% | 32.8% | 8.0% | -13.8% | -155.1% | -44.7% |
| ROIC | 42.0% | 42.0% | 38.9% | 41.2% | 36.2% | 62.3% | 20.4% | -57.0% | — |
| ROCE | 22.6% | 22.6% | 25.9% | 30.9% | 24.7% | 26.0% | 9.0% | -172.8% | -50.5% |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.28 | 0.28 | 0.28 | 0.41 | 0.48 | 1.05 | 2.00 | — | 3.98 |
| Debt / EBITDA | 1.02 | 1.02 | 0.84 | 0.89 | 1.33 | 1.84 | 7.14 | — | — |
| Net Debt / Equity | — | -0.59 | -0.41 | -0.25 | -0.13 | -0.21 | -0.35 | — | 2.95 |
| Net Debt / EBITDA | -2.19 | -2.19 | -1.26 | -0.55 | -0.36 | -0.36 | -1.26 | — | — |
| Debt / FCF | — | -1.47 | -1.24 | -0.54 | -0.36 | -0.39 | — | — | — |
| Interest Coverage | 15.68 | 15.68 | 11.96 | 8.30 | 6.57 | 2.55 | -0.31 | -24.03 | — |
Net cash position: cash ($753M) exceeds total debt ($240M)
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 3.60 | 3.60 | 3.31 | 2.75 | 5.07 | 5.29 | 1.95 | 1.58 | 11.99 |
| Quick Ratio | 3.58 | 3.58 | 3.27 | 2.72 | 5.02 | 5.21 | 1.93 | 1.53 | 11.99 |
| Cash Ratio | 3.08 | 3.08 | 2.67 | 2.16 | 4.10 | 4.36 | 1.70 | 1.23 | 11.55 |
| Asset Turnover | — | 0.68 | 0.72 | 0.72 | 0.65 | 0.70 | 0.37 | 0.06 | — |
| Inventory Turnover | 37.02 | 37.02 | 21.79 | 22.61 | 19.43 | 12.53 | 7.26 | 1.45 | — |
| Days Sales Outstanding | — | 40.68 | 42.40 | 46.49 | 45.63 | 41.64 | 50.67 | 259.06 | — |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | 9.1% | 7.2% | 7.3% | 6.6% | 5.4% | 1.4% | — | — | — |
| FCF Yield | 16.9% | 15.9% | 11.0% | 11.2% | 4.3% | 3.9% | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 5.1% | 0.0% | 0.0% | 0.0% | — | — |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 5.1% | 0.0% | 0.0% | 0.0% | — | — |
| Shares Outstanding | — | $59M | $58M | $60M | $61M | $59M | $58M | $64M | $49M |
Includes 30+ ratios · 8 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying HRMY stock.
Harmony Biosciences Holdings, Inc.'s current P/E ratio is 11.0x. The historical average is 27.0x.
Harmony Biosciences Holdings, Inc.'s current EV/EBITDA is 5.7x. This enterprise value multiple compares the company's total value (equity + debt - cash) to its EBITDA. The historical average is 24.3x.
Harmony Biosciences Holdings, Inc.'s return on equity (ROE) is 20.8%. This is above the typical threshold of 15-20% considered good for most companies. The historical average is -51.0%.
Based on historical data, Harmony Biosciences Holdings, Inc. is trading at a P/E of 11.0x. Compare with industry peers and growth rates for a complete picture.
Harmony Biosciences Holdings, Inc. has 77.2% gross margin and 24.0% operating margin. Operating margin above 20% indicates strong pricing power and cost efficiency.
Harmony Biosciences Holdings, Inc.'s Debt/EBITDA ratio is 1.0x, indicating moderate leverage. A ratio below 2x is generally considered financially healthy.
Key Metrics
Top Statement Risk
Single-product revenue concentration
Metrics are mathematically derived from official filings.
Discount Multiples Reflect Single-Product Risk
Based on reported figures, HRMY trades at a trailing P/E of 12.22 and EV/EBITDA of 6.00, well below peers such as Jazz and Supernus, which carry negative earnings or EBITDA multiples above 24 times.
The compressed trailing multiple suggests the market is pricing HRMY as a mature single-asset business rather than a growth biotech, and the forward P/E of 8.77 implies the market expects earnings to rise meaningfully. Relative to its own history, the stock appears inexpensive on earnings, but the discount may be warranted given that WAKIX still generates the bulk of revenue and year-over-year growth slowed to 12.3% in the latest quarter. Investors should monitor whether the forward earnings expectation holds, since a sustained multiple discount would likely persist until the diversification thesis is demonstrated in reported results.
Margin Compression Outpaces Operating Gains
As reported in the quarterly income data, gross margin fell from 82.7% in 2025Q1 to 70.0% in 2026Q3, while operating margin ranged between 12.4% and 34.2% over the same ten quarters, indicating volatile earning power.
The roughly 13-point gross margin compression appears driven by gross-to-net adjustments and tiered royalty obligations rather than a single event, which suggests pricing pressure may be structural rather than transitory. Operating margin volatility, with R&D rising against a relatively fixed cost base, indicates that operating leverage is not yet consistently flowing to the bottom line. Net margin of 17.9% in the latest quarter should be read against the lumpy quarterly pattern, and investors should treat any single-quarter margin as a weak proxy for normalized earning power.
Returns Decaying Despite Expanding Equity
Based on the ten-quarter ratio series, ROIC declined from a peak of 13.0% in 2025Q3 to 6.9% in 2026Q3, while ROE fell from 8.1% to 4.7% as the equity base grew toward $1.1B.
The decline in ROIC and ROE alongside a growing equity base suggests that incremental capital is being retained in cash and low-return assets, a pattern consistent with a business accumulating liquidity rather than compounding capital. The drop in returns appears driven more by margin compression than by asset efficiency, since asset turnover has remained relatively stable. Investors should watch whether returns recover as margins stabilize, because the current trajectory indicates capital is not yet being deployed at the rates implied by reported profitability.
Working Capital Cycle Tightening Steadily
According to the reported ratio data, the cash conversion cycle compressed from 44 days in 2024Q2 range to 20 days in 2026Q3, driven largely by a longer DPO that rose from 28 days to a peak of 55 days before easing.
The shortening cash conversion cycle suggests improved working capital discipline, though the reliance on supplier payment timing is a meaningful contributor rather than purely operational improvement. DSO remained fairly stable near 0.2 turns of receivables, indicating that customer collection behavior has not been the source of change. Analysts should distinguish between efficiency gains and timing effects, since a reversal in DPO could erase much of the cash benefit.
Minimal Debt With Comfortable Coverage
As reported in the balance sheet data, debt-to-equity fell from 0.35 in 2024Q2 to 0.14 in 2026Q3, and interest coverage stood at 20.36 times in the latest quarter, indicating very low financial risk.
The declining leverage and high coverage ratio suggest debt service poses little strain on reported cash flows, and the balance sheet offers a meaningful buffer should revenue soften. Debt-to-EBITDA of 2.48 is modest, though quarterly EBITDA volatility means the ratio has ranged from 1.62 to 6.90 over the period. Investors may wish to monitor the trajectory, but refinancing risk appears limited based on the reported figures.
Liquidity Buffer Exceeds Operating Needs
Based on reported figures, the current ratio held between 3.13 and 3.84 across all ten quarters, with cash reaching $647.1M in 2026Q3, providing a substantial buffer against near-term obligations.
The consistently high current ratio and quick ratio near 3.4 suggest that short-term liabilities are well covered even without relying on inventory, which is modest given the specialty-pharmacy channel structure. Under a severe revenue shock tied to WAKIX pricing or supply disruption, the cash position would likely sustain operations for an extended period, though the reported figures do not disclose a formal stress scenario. The main consideration is whether this liquidity is being deployed productively, since a large idle cash balance weighs on return metrics.
Peer Multiples Mislead on Single-Asset Business
As reported in the peer data, HRMY's P/E of 12.22 looks cheap against loss-making peers, yet the comparison may overstate value since Jazz and Supernus carry negative earnings that distort multiple-based relative valuation.
Peer multiples with negative denominators are not meaningful, so the apparent discount to Jazz and Supernus reflects measurement limits more than relative cheapness. A more informative lens is cash-adjusted enterprise value against WAKIX-specific gross profit, which would isolate how much of the valuation rests on one product. Investors should weigh the low multiple against unresolved concentration and litigation exposure before treating it as evidence of undervaluation.